Biotech Values

[floblu14]

PHARMACEUTICAL TECHNOLOGY research news via GlobalData -

March 29, 2024
Enanta Pharmaceuticals gets grant for inhibiting coronavirus replication with compound of formula (i)

Enanta Pharmaceuticals has been granted a patent for compounds that inhibit coronavirus replication. The patent covers pharmaceutical compositions and methods for treating or preventing coronavirus infections. Claim 1 specifically pertains to a compound represented by Formula (I).

Excerpts:
Additionally, the patent includes claims for pharmaceutical compositions comprising the disclosed compound and methods for treating or preventing virus infections, specifically coronavirus infections such as those caused by 229E, NL63, OC43, HKU1, SARS-CoV, or MERS coronavirus.

The patent's claims highlight the compound's versatility in treating various virus infections and respiratory disorders, positioning it as a valuable asset in the field of antiviral and respiratory therapeutics.

Read more:
https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-inhibiting-coronavirus-replication-with-compound-of-formula-i/